Improvement of Liver Cancer Detection with Simultaneous Assessment of Circulating Levels of Free Alpha-Fetoprotein (AFP) and Afp-Igm Complexes

Beneduce, Luca; Castaldi, F; Marino, M.; Tono, Natascia; Gatta, Angelo; Pontisso, Patrizia; Fassina, Giorgio

doi:10.1177/172460080401900211

Cited by 46 publications

(38 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The detection ratio in liver cancer was significantly higher compared to any other type of tumor. This is inconsistent with the literature, where AFP is considered to be the specific diagnosis index for liver cancer (44). When combined with other markers, AFP sensitivity increases significantly (44).…”

Section: Sensitivity % (N) -----------------------------------------contrasting

confidence: 55%

“…This is inconsistent with the literature, where AFP is considered to be the specific diagnosis index for liver cancer (44). When combined with other markers, AFP sensitivity increases significantly (44). However, AFP also elevates in non-tumor diseases, such as acute and chronic hepatitis and cirrhosis (45).…”

Section: Sensitivity % (N) -----------------------------------------contrasting

confidence: 54%

See 1 more Smart Citation

Combining multiple serum biomarkers in tumor diagnosis: A clinical assessment

Lü

Ren

et al. 2012

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The present study aimed to assess the diagnostic/ prognostic value of various clinical tumor markers, including carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cytokeratin 19 (CYFRA21-1), α-fetoprotein (AFP), carbohydrate antigen-125 (CA-125), carbohydrate antigen-19.9 (CA-19.9) and ferritin, individually or in combination. The electro-chemiluminescence immunization method was performed to detect the levels of seven tumor markers in 560 cancer patients and 103 healthy subjects for comparison. The serum levels of the seven markers measured in cancer patients were higher compared to healthy subjects (P<0.05 for AFP and P<0.001 for the remaining six markers). Different markers had different sensitivity towards different types of tumors. Combining more markers significantly increased the ratios of positive diagnosis in the tumors. The diagnostic sensitivities of combining seven markers were particularly high in digestive, urinary and skeletal tumors (82, 92 and 83%, respectively). Gynecological tumors have exhibited a constant yet relatively low positive diagnosis irrespective of the use of a single marker or combined markers. However, the increase in sensitivity when combining markers was accompanied by a decrease in specificity. Generally, combining more markers increased the tumor detection rates, while a combination of the seven markers provided the highest detection rate. Combined detection showed a particularly high sensitivity in detecting respiratory, digestive and urinary system tumors, with the lowest sensitivity observed in gynecological tumors. As a result, combining tumor markers may play an important role in early tumor detection/diagnosis while the loss of specificity can be tolerated.

show abstract

Section: Sensitivity % (N) -----------------------------------------contrasting

confidence: 55%

Section: Sensitivity % (N) -----------------------------------------contrasting

confidence: 54%

Combining multiple serum biomarkers in tumor diagnosis: A clinical assessment

Lü

Ren

et al. 2012

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Multivalent IgMs are usually considered the main component of innate immunity, with the binding capacity for a wide range of tumour markers (24,25). The occurrence of IgM immune complexes with diagnostic value has been found in different human tumours (6)(7)(8)(9)(10), and also in other pathologic conditions (26,27).…”

Section: Discussionmentioning

confidence: 99%

“…At present, a large number of animal studies (3) and clinical observations in humans (4,5) provide evidence supporting the cancer immunoediting theory. In patients with different types of cancer including liver, colorectal and prostate cancer, it is possible to detect immunoglobulin M (IgM) antibodies bound to cancer biomarkers (6)(7)(8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis

Zuin¹,

Veggiani²,

Pengo³

et al. 2009

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Background: Squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) is a useful biomarker for the risk of development of hepatocellular carcinoma (HCC) in patients with cirrhosis due to its progressive increase associated to HCC evolution. In patients with cirrhosis, other assays have been affected by interfering reactivities of IgM. In this study, the analytical specificity of the SCCA-IgM assay was assessed by evaluating SCCA-IgM measurement dependence on different capture phases, and by measuring the recovery of SCCA-IgM reactivity following serum fractionation. Methods: Serum samples from 82 patients with cirrhosis were analyzed. SCCA-IgM was measured using the reference test (Hepa-IC, Xeptagen, Italy) that is based on rabbit oligoclonal anti-squamous cell carcinoma antigen (SCCA) and a dedicated ELISA with a mouse monoclonal anti-SCCA as the capture antibody. Results: SCCA-IgM concentrations measured with the reference assay (median values87 AU/mL) were higher than those measured with the mouse monoclonal test (median values78 AU/mL). However, the differences in the SCCAIgM distribution were not statistically significant (p)0.05). When SCCA-IgM concentrations measured with both tests were compared, a linear correlation was found (rs0.77,

show abstract

“…The presence of IgM-linked immune-complexes with diagnostic value has been found recently in different human tumours, including colon [21] and prostate cancer [22] , and also in other pathologic conditions [23] . For liver disease, the diagnostic value of squamous cell carcinoma antigen-IgM (SCCA-IgM) immune-complex in serum has been demonstrated in several studies [24,25] . In this review we summarize the role of SCCAIgM as a novel promising tool to monitor liver disease evolution and response to antiviral treatment in patients with chronic hepatitis C; we also analyze the value of this biomarker for the diagnosis and prognosis of HCC.…”

Section: Introductionmentioning

confidence: 99%

Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C

Martini

Gallotta

Pontisso

et al. 2015

WJH

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is the main cause of chronic liver disease and cirrhosis in Western countries. Over time, the majority of cirrhotic patients develop hepatocellular carcinoma (HCC), one of the most common fatal cancers worldwide -fourth for incidence rate. A high public health priority need is the development of biomarkers to screen for liver disease progression and for early diagnosis of HCC development, particularly in the high risk population represented by HCV-positive patients with cirrhosis. Several studies have shown that serological determination of a novel biomarker, squamous cell carcinoma antigen-immunoglobulins M (SCCA-IgM), might be useful to identify patients with progressive liver disease. In the initial part of this review we summarize the main clinical studies that have investigated this new circulating biomarker on HCV-infected patients, providing evidence that in chronic hepatitis C SCCA-IgM may be used to monitor progression of liver disease, and also to assess the virological response to antiviral treatment. In the last part of this review we address other, not less important, clinical applications of this biomarker in hepatology. Core tip: A high public health priority need is the development of biomarkers to screen for liver disease progression in hepatitis C virus (HCV)-positive patients. Serological squamous cell carcinoma antigen-immunoglobulins M has shown the ability to identify patients with progressive liver disease and patients at higher risk of hepatocellular carcinoma development. In this review we summarize the main clinical studies performed using this new circulating biomarker for monitoring cirrhosis progression in HCV-positive patients and to evaluate virological response to antiviral treatment. Clinical applications of squamous cell carcinoma antigenimmunoglobulins M to monitor chronic hepatitis C Martini A, Gallotta A, Pontisso P, Fassina G. Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C. MINIREVIEWS

show abstract

Improvement of Liver Cancer Detection with Simultaneous Assessment of Circulating Levels of Free Alpha-Fetoprotein (AFP) and Afp-Igm Complexes

Cited by 46 publications

References 14 publications

Combining multiple serum biomarkers in tumor diagnosis: A clinical assessment

Combining multiple serum biomarkers in tumor diagnosis: A clinical assessment

Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis

Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C

Contact Info

Product

Resources

About